Allergan, Perrigo gain approval for store-brand Mucinex DM

DUBLIN - Allergan and its partner Perrigo announced Thursday that Allergan has received U.S. Food and Drug Administration approval for its abbreviated new drug applications for three Mucinex equivalent products, including Mucinex DM Regular Strength (guaifenesin 600mg and dextromethorphan 30mg), Mucinex DM Maximum Strength (guaifenesin 1200mg and dextromethorphan 60mg) and Mucinex Maximum Strength (guaifenesin 1200mg). 

 

Perrigo will begin shipments of the products to its retail and wholesale customers in the U.S in time for the 2016 cough and cold season. 

 

Mucinex Maximum Strength is an expectorant indicated to relieve chest congestion and thin and loosen mucus.  Sales for the last 12 months were $73 million. Mucinex DM Regular and Maximum Strengths sales for the last 12 months were $67 million and $104 million, respectively.

 

"These approvals are a significant milestone in the partnership between Perrigo and Allergan, and we are pleased to be the first company to bring these difficult to manufacture products to the market," stated Joseph Papa, Perrigo president and CEO.